Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) has reached a settlement with Jazz Pharmaceuticals (Nasdaq: JAZZ) that resolves patent litigation related to the Ireland-based company’s Xyrem (sodium oxybate) oral solution, 500mg/mL product.
Jazz will grant Hikma and its subsidiary, West-Ward Pharmaceuticals, the right to sell an authorized generic (AG) of Xyrem in the US market from January 1, 2023, or earlier under certain circumstances.
Used to treat cataplexy (sudden loss of muscle strength) and reduce daytime sleepiness in patients with narcolepsy, Xyrem net sales for 2016 earned Jazz $1.11 billion, according to the company’s annual report.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze